PVLA Stock Analysis: Buy, Sell, or Hold?
PVLA - Palvella Therapeutics, Inc. Common Stock
$139.04
-11.15 (-7.42%)
▼
5d:
+0.75%
30d:
+0.56%
90d:
+8.35%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 04, 2026
TODAY
Get Alerted When PVLA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PVLA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: PVLA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: PVLA is currently trading at $139.04, which is considered slightly low relative to its 30-day fair value range of $137.10 to $151.38.
Technical Outlook: Technically, PVLA is in a uptrend. Immediate support is located at $120.61, while resistance sits at $157.55. Short-term momentum is weak, with the stock down 7.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $229.60 (+65.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PVLA is in a uptrend. Immediate support is located at $120.61, while resistance sits at $157.55. Short-term momentum is weak, with the stock down 7.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $229.60 (+65.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$137.10 -
$151.38
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.4%)
- BULLISH: Trading 65.1% below Wall St target ($229.60)
Trading Range Analysis
30-Day Trading Range
$137.10 -
$151.38
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$13.00
(9.3%)
Support & Resistance Levels
Support Level
$120.61
Resistance Level
$157.55
Current Trend
Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-21.78
Wall Street Target
$229.60
(+65.1%)
Share & Embed Analysis
Last updated: August 02, 2026 10:36 PM ET
Data refreshes hourly during market hours. Next update: 11:36 PM
Data refreshes hourly during market hours. Next update: 11:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PVLA showing a specific setup today?
Insider Activity (6 Months)
2
Buys
1
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Kathleen Goin
SELL
4302 shares
2026-03-18
Elaine J Heron
BUY
2400 shares
2026-02-27
George M Jenkins
BUY
4000 shares
2026-02-27
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 57 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
